Crossmark

End-of-life decision-making across cancer types: results from a nationwide retrospective survey among treating physicians

Crossref DOI link: https://doi.org/10.1038/s41416-018-0070-5

Published Online: 2018-03-29

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Verkissen, Mariëtte N.

Houttekier, Dirk

Cohen, Joachim

Schots, Rik

Chambaere, Kenneth

Deliens, Luc
License Information

Text and Data Mining valid from 2018-03-29
More Information

Article History

Received: 13 September 2017

Revised: 28 February 2018

Accepted: 7 March 2018

First Online: 29 March 2018

Competing interests

: R.S. has reported that he has received honoraria for attendance at advisory board meetings from Celgene, Takeda, AbbVie, and Amgen. He has also received travel funding from Bristol-Myers Squibb (BMS) to attend the American Society of Hematology 2016 Annual Meeting (December 2016). All remaining authors declare no competing interests.

: Ethical approval was obtained from the Ethical Review Board of the University Hospital of the Vrije Universiteit Brussel (ref no. 143201316288, 8 February 2013). Patients were deceased, and consent was not required. Physicians’ participation was regarded as implicit consent, which was noted in the accompanying letter introducing the study.